

ASX Announcement

Cancer vaccine shows early promise in gastric cancer clinical trial

- Strong immune responses measured in the first patients dosed
- Dose escalation recommended after no safety, toxicity or tolerability issues
- Clinical data will guide recommended dose for planned Phase 2 study

MELBOURNE Australia 07 February 2018: Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company is pleased to announce its HER-Vaxx cancer vaccine (IMU-131) is showing early promise in patients with metastatic gastric cancer and feedback from clinicians running the study has been positive.

Clinicians have reported no safety, toxicity or tolerability issues with HER-Vaxx during the first cohort dosing of patients.

Lead investigator Professor Dr. Christoph Zielinski said, "The Cohort Review Committee for the study recently reviewed the results and has recommended dose escalation."

Clinicians at eight sites across Hong Kong, Taiwan and Thailand will also determine if the administration of HER-Vaxx in combination with chemotherapy will prolong survival, delay tumor progression, or reduce the tumor burden in patients with metastatic gastric cancer.

Professor Zielinski added, "Unlike Herceptin® and Perjeta®, which are "injected synthetic antibody" products, HER-Vaxx activates the patient's own immune system to produce a continuous supply of cancer targeting antibodies and induce a response against the tumors as we see with Herceptin and Perjeta."

The clinical results indicate that IMU-131 induces strong immune responses in patients, with antibodies to the target cancer biomarker HER2/neu strongly evident in validated assays.

Imugene Chief Scientific Officer Professor Dr. Ursula Wiedermann said, "We are pleased that there were no safety issues reported from the Cohort Review Committee. The early clinical data is also encouraging, indicating immune activation in vaccinated patients in a manner that is consistent with the vaccine's postulated mechanism of action."

Imugene Chief Executive Officer Leslie Chong said, "We are pleased with the results that we have seen so far. There is no observed toxicity and observing strong immune responses is exciting. Everyone supporting the study and involved in developing this important new cancer therapy are very encouraged by the progress to date. We look forward to completing the rest of the trial and reporting to the market further developments."

For personal use only

For further information please contact:
Leslie Chong
Chief Executive Officer
E: Leslie.Chong@Imugene.com

About Imugene (ASX:IMU)

Imugene (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Developed by leading scientists at the Medical University of Vienna in Austria, the peptide vaccine is constructed from several B cell epitopes of HER-2/neu. It has been shown in pre-clinical studies and in one Phase I study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.

Imugene in partnership with the Medical University of Vienna is working to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This partnership has the potential to create game-changing B cell peptide vaccines that would replace or augment conventional monoclonal antibody therapies.